The therapies in question, including the monoclonal antibodies lecanemab and donanemab, represent a genuine pharmacological milestone. By binding to amyloid-beta plaques in the brain and recruiting immune mechanisms to clear them, these agents can slow clinical progression in appropriately selected patients with early symptomatic Alzheimer’s disease. But their power comes with a formidable operational burden. Before a patient can receive an infusion, clinicians must confirm the diagnosis through specialized workups that may include amyloid PET imaging or cerebrospinal fluid biomarkers, exclude contraindications such as anticoagulant use or advanced atrophy on MRI, and carefully stage the disease. After treatment begins, patients require repeated MRI scans to watch for amyloid-related imaging abnormalities, or ARIA, a spectrum of brain edema and microhemorrhage that is usually asymptomatic but can, in rare cases, become serious or even fatal. Managing that risk demands fluency in neuroradiology, pharmacology and infusion nursing that most community practices have never needed to assemble.

That gap between what the drugs demand and what most health systems possess is stark at Sutter. The not-for-profit system cares for more than 3.6 million patients and employs more than 100 general neurologists, yet it has only five cognitive and behavioral neurologists, concentrated at two specialty memory centers. The arithmetic is unforgiving: if every candidate for amyloid-targeting therapy had to be evaluated, treated and monitored exclusively by those five subspecialists, access would be rationed by geography and waiting lists. Instead of funneling patients into tertiary centers, Sutter inverted the model. It created the Advanced Therapeutics for Alzheimer’s Disease, or ATAD, Review Board, a weekly virtual session that projects subspecialty expertise outward to neurologists across the entire system, keeping the patient’s care anchored in their own community.

The mechanics of the review board are deceptively simple but operationally sophisticated. Each session convenes cognitive neurologists, a neuroradiologist, a pharmacist and a registered nurse program manager, who together examine referred cases submitted by general neurologists. The board evaluates diagnostic evidence, weighs eligibility criteria, reviews MRI findings for ARIA risk and helps interpret ambiguous biomarker results. Crucially, the local neurologist retains responsibility for prescribing, follow-up and ongoing monitoring; the board functions as an advisory layer that supports eligibility decisions and can be consulted when side effects emerge during the treatment course. The design also works as a learning network: referring clinicians can join case discussions, receive the reasoning behind each eligibility determination and re-refer patients whenever new questions arise mid-treatment, so that expertise accumulates in the community over time rather than remaining locked inside the memory centers.

The published outcomes suggest the model is working at scale. From November 2023 through December 2025, the board received 574 referrals. The analysis focused on 447 fully reviewed cases submitted by 51 general neurologists, and 344 of those patients, or 77 percent, were judged eligible for treatment. Referral volume surged 148 percent year over year, from 163 cases in 2024 to 404 in 2025, a signal that community neurologists increasingly embraced the pathway as it matured. Of the eligible patients, 214 ultimately began an amyloid-targeting therapy through general neurology, meaning the majority of treated patients in this cohort never needed to rely on a subspecialist as their primary prescriber.

The safety data are the most closely watched element of the report, and they are broadly reassuring. Among treated patients, the rate of any radiographic ARIA was 17.4 percent for those receiving lecanemab and 28.8 percent for those receiving donanemab. Symptomatic ARIA, the clinically meaningful subset, occurred in just 2.6 percent and 1.7 percent of patients respectively. The authors note that these rates were lower than those observed in the pivotal phase 3 clinical trials and consistent with real-world studies emerging from specialty memory clinics, suggesting that community-based delivery did not compromise safety. They are careful, however, to flag a likely contributor to the favorable numbers: patient selection, including a lower proportion of patients carrying the higher-risk APOE epsilon 4 genotype, which is associated with elevated ARIA susceptibility, may have shaped the observed rates. The manuscript also reports two deaths among patients on treatment and explicitly acknowledges uncertainty about whether the therapies contributed, a candid note that underscores the necessity of careful counseling and vigilant monitoring regardless of where care is delivered.

What distinguishes the Sutter approach from a purely clinical observation is its institutional embedding. The ATAD Review Board sits within Sutter’s Neuroscience Service Line, which funded the program infrastructure, established a consistent workflow and disseminated updated clinical guidance across the system. The model knits together specialty memory expertise with community neurology, imaging services, pharmacy, infusion resources and nursing support into a single coordinated pathway. In an integrated delivery system, that architecture allows evidence and expertise to travel to the patient rather than requiring every patient to travel to a tertiary center for every aspect of care, a distinction that becomes decisive when the eligible population numbers in the thousands and the specialist workforce numbers in the single digits.

The leadership behind the program frames it as a proof of concept for system-level medicine. Armen Moughamian, M.D., Ph.D., the article’s lead author, chief of memory for Sutter’s Neuroscience Service Line and medical director of the Ray Dolby Brain Health Center at Sutter’s CPMC, emphasized that these therapies offer new hope but that putting them into everyday practice safely takes far more than writing a prescription, and that the model brings the right expertise to the patient’s local neurologist so more people can be evaluated closer to home while preserving rigorous review, monitoring and shared decision-making. Shawn Kile, M.D., chair of the Neuroscience Service Line and a co-author, described the service line as designed to move expertise, evidence and support across the system, noting that ATAD shows how an integrated system can translate scientific advances into coordinated, local care while keeping patient safety at the center.

The broader significance of the findings lies in reframing the challenge of Alzheimer’s innovation. The pivotal trials of lecanemab and donanemab answered whether amyloid removal slows decline; they did not answer how a nation with a severe shortage of dementia specialists can administer these regimens to a population that skews rural, elderly and geographically dispersed. The Sutter model offers one template: pair local prescribing and follow-up with centralized multidisciplinary oversight, and use the review process itself as a vehicle for training community clinicians. The authors propose that similar review boards could help other health systems expand access while maintaining specialist input, an approach that could prove especially valuable for systems that, like Sutter, have many general neurologists but few cognitive specialists.

Important caveats temper the enthusiasm. The article is a perspective describing implementation and observational outcomes, not a randomized trial, so the safety figures reflect a selected population and a self-referred cohort rather than an experimental comparison. No external funding supported the data collection or manuscript preparation, and the authors themselves caution that favorable ARIA rates may partly reflect conservative patient selection. Still, as amyloid-targeting therapies move from trial protocols into routine practice, the Sutter experience provides a concrete, quantified demonstration that the bottleneck in Alzheimer’s care is not scientific but logistical, and that a weekly virtual meeting of five kinds of expertise may be enough to break it.

Subject of Research: A multidisciplinary virtual review board model for expanding community access to amyloid-targeting Alzheimer's disease treatments

Article Title: Sutter examines how health systems can expand access to new Alzheimer’s treatments

Article References: Sutter examines how health systems can expand access to new Alzheimer’s treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, amyloid-targeting therapies, lecanemab, donanemab, ARIA, general neurology, health system delivery, Sutter Health, cognitive neurology, virtual review board, patient safety, health care access

The modeling effort drew on the Schaeffer Center’s U.S. Cost of Dementia Project, a federally funded initiative built to quantify the full economic burden of dementia in the United States. Using a dynamic microsimulation framework, the researchers constructed a virtual cohort closely resembling participants from the pivotal Phase 3 clinical trial of donanemab. They then compared three scenarios: receiving treatment on the schedule used in the trial, starting treatment two years earlier while still after the point at which symptoms usually emerge, and receiving no treatment at all. Crucially, the estimates capture the value of health improvements and economic benefits alone, deliberately excluding the costs of the drug itself as well as the screening and monitoring infrastructure required to deliver it.

To ground the simulation in real-world biology, the team incorporated a 29 percent slowing of disease progression for both treatment groups, matching the results donanemab achieved against placebo after 18 months in the trial. Cognitive status over each simulated lifetime was tracked using a commonly used scoring measure, calibrated with data from large national health surveys and longitudinal studies of dementia progression. This approach allowed the researchers to translate a clinical trial endpoint into something more meaningful for patients, families, and public budgets: years of life, years lived independently, and years spared from severe dementia.

The projected benefits for the trial-timing group were modest but consequential. Compared with untreated individuals, patients treated during the clinical trial were expected to live about 0.3 years longer, spend one full year less with severe dementia, gain 0.37 disability-free years, and remain living in the community for an additional 0.63 years. Those gains accumulated into the $104,900 lifetime societal value per person. Roughly half of that total, $52,300, came from improved health-related quality of life. Reductions in unpaid caregiving contributed $23,800, while medical cost offsets added $22,200, a share that accrued largely to Medicaid. On an annual basis, the model estimated that Medicaid costs fell by about $1,640 per treated patient, a 13 percent reduction.

Shifting the start of treatment two years earlier amplified every one of those measures. Because the therapy slows cognitive decline earlier in the disease course, patients spend more of their lives in earlier, more functional stages of Alzheimer’s, and the downstream savings compound. Lifetime value rose 32 percent to $138,300. The researchers also tested a scenario informed by emerging evidence suggesting that earlier treatment may produce an even stronger slowing effect, and under those assumptions the value climbed 71 percent above the clinical trial group, reaching $179,400. In other words, the window between the first subtle symptoms and a formal diagnosis may represent some of the most valuable real estate in Alzheimer’s medicine.

The study’s authors are careful to acknowledge the uncertainty inherent in evaluating therapies that have only recently entered clinical use. Because anti-amyloid treatments are so new, no one yet knows how long their benefits will persist. In a deliberately conservative scenario in which the treatment effect lasts only four years rather than for the remainder of a patient’s life, the projected lifetime value was cut roughly in half, to $49,100. Yet even under that pessimistic assumption, earlier initiation still produced 15 percent more value, at $56,400. The direction of the finding, the researchers note, is robust: whenever treatment helps, starting sooner helps more.

The economic stakes of getting this right are enormous. Alzheimer’s disease and related dementias are projected to cost the United States an estimated $818 billion in 2026, a figure expected to grow steadily as the population ages. Against that backdrop, understanding how the long-term benefits of treatment vary with the timing of initiation could inform decisions about how to expand access sustainably and where each new dollar of investment delivers the greatest impact. The analysis suggests that coverage policies and health system investments should be evaluated not only on whether patients receive therapy, but on when they receive it.

One of the most striking numbers in the study concerns the diagnosis gap itself. On average, Alzheimer’s disease is diagnosed 3.5 years after symptoms first appear, leaving a critical and largely unexploited opportunity for earlier intervention. That delay has historically been driven by the difficulty and expense of confirming the disease, which often required costly imaging or invasive procedures. But the diagnostic landscape is changing rapidly. Several blood-based biomarker tests approved by the U.S. Food and Drug Administration within the past year, along with new digital cognitive assessments, could make it substantially easier to identify Alzheimer’s in its earlier stages and connect patients to treatment while the therapies retain their greatest potential.

Lead author Jack Chapel, a USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy, framed the findings as a call to invest in the front end of the care pathway. New therapies and diagnostic tools, he noted, are making it possible to alter the course of Alzheimer’s disease, but they come with considerable costs, and the research suggests that investments in early detection could help ensure patients begin treatment when it is most likely to deliver the greatest benefit to patients and society alike. Every year between the first symptoms and a diagnosis, the study argues, is value lost for patients, their families, and the public programs that ultimately pay for dementia care.

The analysis also looks beyond today’s therapies toward the next generation. More than 150 potential Alzheimer’s treatments are currently undergoing clinical testing, and the researchers modeled what future advances might be worth if they achieve greater degrees of disease modification. A hypothetical treatment slowing progression by 50 percent would generate an estimated lifetime social value of $208,700 to $276,700 per person, depending on when treatment begins. A treatment that completely halts progression would more than double that, with estimated values ranging from $530,000 to $648,300. As therapies and diagnostics continue to improve, the authors conclude, the case for finding and treating people sooner only grows stronger, transforming early detection from a convenience into a central pillar of Alzheimer’s care and health policy.

Subject of Research: Economic modeling of the lifetime societal value of early-initiated anti-amyloid therapy for Alzheimer's disease

Article Title: Starting Alzheimer’s treatment earlier increases benefits to patients and society

Article References: Starting Alzheimer’s treatment earlier increases benefits to patients and society. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, donanemab, anti-amyloid therapy, early detection, blood biomarkers, health economics, microsimulation, Medicaid, dementia costs, USC Schaeffer Center, clinical trials, caregiving

The immediate trigger for Owen’s intervention is a recent Cochrane systematic review, led by Nonino and colleagues, which concluded that amyloid-beta-targeting monoclonal antibodies offer no clinically meaningful benefit to people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The review’s publication provoked sharp criticism from within the Alzheimer’s research community, but Owen observes that much of that criticism focused on the review’s methodology, on questions of statistical pooling, trial selection and effect-size calculation, rather than on the underlying clinical case for the drugs themselves. In his view, this deflection represents a missed opportunity. Rather than interrogating whether the treatments help patients in ways that matter in daily life, the debate has circled technical questions that leave patients, families and clinicians without a clear answer.

At the heart of the controversy lies a deceptively simple question: what does a ‘modest’ or ‘moderate’ benefit actually mean for a person living with early Alzheimer’s disease? The pivotal trials of lecanemab, reported in the New England Journal of Medicine by van Dyck and colleagues in 2023, and of donanemab, reported in JAMA by Sims and colleagues in the TRAILBLAZER-ALZ 2 trial, both demonstrated statistically significant slowing of decline on the Clinical Dementia Rating Scale Sum of Boxes, a standard instrument for staging dementia that was first described by Hughes and colleagues in 1982. But statistical significance is not the same as clinical meaning. A change on a rating scale, even one that reaches conventional thresholds for significance, may translate into differences in daily functioning that are imperceptible to patients and their caregivers, or it may not. Owen’s Comment presses precisely on this gap between the numbers reported in trial publications and the lived reality of the disease.

The problem of defining clinically meaningful outcomes is not unique to Alzheimer’s research, but it is unusually acute there. A 2025 review by Stoeckel and colleagues examined what constitutes clinically meaningful outcomes in Alzheimer’s disease and related dementia trials, and a 2024 rapid review by Muir and colleagues tackled the related concept of the minimal clinically important difference in the disease. Both underline a persistent difficulty: the field has lacked consensus on how large an effect must be, and on which measures, before it can honestly be described as beneficial to a patient. Without such consensus, terms like ‘modest’ and ‘moderate’ float free of any anchor, allowing advocates and skeptics to describe the same trial results in dramatically different terms. Owen argues that this ambiguity is not an accident of imprecise language but a structural feature of how the field has communicated its results, and one that has gone largely unexamined.

One way to calibrate expectations is to compare the anti-amyloid drugs against other interventions whose effects are better understood. Cognitive training and cognitive stimulation therapies, which aim to maintain or improve thinking skills through structured mental activity, have been studied for decades with rigorous randomised controlled designs. Work by Huntley, Hampshire and Owen himself in 2017 tested adaptive working memory strategy training in early Alzheimer’s disease, and broader meta-analyses by Zhang and colleagues in 2019 and Chan and colleagues in 2024 have synthesised the effects of computerised cognitive training in mild cognitive impairment. Cochrane reviews by Bahar-Fuchs and colleagues and meta-analyses of cognitive stimulation therapy by Desai and colleagues and by Spector and colleagues provide further benchmarks. These interventions produce effects on cognitive measures that are, in many cases, comparable in magnitude to those reported for anti-amyloid antibodies, yet they are rarely described in the triumphant language that has accompanied the new drugs. That asymmetry, Owen suggests, is itself informative about how the field weighs evidence.

The history of the amyloid programme also includes sobering episodes that complicate the narrative of steady progress. Aducanumab, the first anti-amyloid antibody to receive accelerated approval, was discontinued as an Alzheimer’s treatment, a decision acknowledged by the Alzheimer’s Association, after a trajectory marked by contested trial results and contentious regulatory review. A 2022 analysis by Kim and colleagues catalogued key insights from two decades of clinical trial failures in Alzheimer’s disease, a record that spans far more than amyloid-targeting agents and reflects the extraordinary difficulty of intervening in a neurodegenerative process that begins years before symptoms appear. Against that backdrop, the licensing of lecanemab and donanemab, with the United States Food and Drug Administration converting one novel treatment to traditional approval in September 2025, represents genuine scientific progress in the narrow sense that amyloid can now be reliably cleared from the brain. The open question is whether plaque removal, on its own, changes the course of the disease in ways patients can feel.

Owen’s Comment also situates the current debate within the broader architecture of Alzheimer’s diagnosis and drug development. Revised criteria for the diagnosis and staging of Alzheimer’s disease, published by Jack and colleagues in 2024 under the auspices of the Alzheimer’s Association Workgroup, have moved the field toward a biological definition of the disease, in which biomarkers of amyloid and tau pathology can establish a diagnosis even in the absence of symptoms. That shift has been celebrated as a way to intervene earlier, before irreversible neuronal loss occurs, but it also raises the stakes of the benefit question: if treatments are to be offered to ever larger populations identified by biomarkers rather than symptoms, the size of the benefit each patient can expect becomes a matter of profound practical importance. The drug development pipeline, surveyed by Cummings and colleagues in 2025, remains crowded with agents, and the proportion of the population carrying risk variants such as APOE4, estimated in pooled analyses of nearly 389,000 community-dwelling individuals by Wang and colleagues, underscores the scale of the population that stands to be affected by these decisions.

What makes Owen’s argument distinctive is not a claim that the trials were flawed or that the drugs are useless, but a call for honesty about the magnitude of their effects and for a vocabulary that patients and clinicians can actually use. The pivotal trials enrolled people with mild cognitive impairment or mild dementia, the earliest symptomatic stages of the disease, precisely because that is where intervention is thought to hold the most promise. In those populations, the reported slowing of decline, while statistically robust, must be weighed against practical realities: the drugs require regular intravenous infusions over extended periods, monitoring with magnetic resonance imaging for a serious side effect known as amyloid-related imaging abnormalities, and careful patient selection. For a patient and family deciding whether to commit to that regimen, the relevant question is not whether a p-value crossed a threshold but whether the treatment will meaningfully extend the time they can live independently, recognise loved ones, or continue the activities that give their lives structure and meaning. Owen contends that the field has not done the work of answering that question in those terms.

The Comment also highlights a striking feature of the public response to the Cochrane review: the speed and intensity with which it was challenged by patient organisations and leading experts, including a public response from the Alzheimer’s Society defending the anti-amyloid drugs as effective. In a field that has endured repeated disappointments, the desire for treatments that finally work is entirely understandable, and patient advocacy has historically been a powerful force for accelerating research and improving access to care. But Owen’s concern is that advocacy, however well intentioned, can short-circuit the kind of critical self-examination that science requires. If the conversation about clinical meaningfulness is framed as an attack on hope rather than as a legitimate scientific question, then the field loses the opportunity to establish, once and for all, what its therapies can and cannot do, and to design the next generation of trials around outcomes that matter.

The stakes of this unresolved conversation extend well beyond the current generation of antibodies. If the field cannot agree on what constitutes a clinically meaningful benefit, then even genuinely transformative therapies of the future may struggle to demonstrate their value, and patients may continue to face difficult decisions armed only with vague descriptors and contested statistics. Owen’s contribution, published as a Neurological Update in the Journal of Neurology and supported by the Canadian Institutes of Health Research, is ultimately an appeal for clarity: for researchers, regulators and clinicians to specify, in concrete and patient-centred terms, what ‘modest’ and ‘moderate’ benefit mean, and to have that discussion openly rather than allowing it to remain the conversation the Alzheimer’s field isn’t having. Whether the field takes up that challenge will shape not only how the current drugs are used, but how the next decades of Alzheimer’s research are judged by the people who matter most, the patients and families living with the disease.

Subject of Research: Clinical meaningfulness of anti-amyloid monoclonal antibody therapies in Alzheimer's disease

Article Title: What have trials targeting amyloid in Alzheimer’s told us to date? The conversation the Alzheimer’s field isn’t having

Article References: Owen, A. M. (2026). What have trials targeting amyloid in Alzheimer’s told us to date? The conversation the Alzheimer’s field isn’t having. Journal of Neurology, 273(10), Article 617. https://doi.org/10.1007/s00415-026-14147-8

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14147-8

Keywords: Alzheimer's disease, anti-amyloid therapies, lecanemab, donanemab, Cochrane review, clinical trials, clinical meaningfulness, amyloid-beta, dementia, cognitive training, biomarkers, drug development